Question 49

Pharmacies must report the theft or significant loss of Carisoprodol to the DEA.

Carisoprodol is classified as a Schedule IV controlled substance, which necessitates reporting any theft or significant loss to the Drug Enforcement Administration (DEA) in accordance with federal regulations.

A) Carbamazepine

Carbamazepine is not a controlled substance under the Controlled Substances Act and therefore does not require reporting to the DEA for theft or significant loss. While it is a prescription medication, it falls outside the category that mandates such reporting.

B) Carbidopa

Carbidopa is not considered a controlled substance and is primarily used in combination with levodopa for the treatment of Parkinson's disease. As it does not fall under DEA regulations, the theft or significant loss of Carbidopa does not need to be reported.

C) Carvedilol

Carvedilol is a non-controlled medication used to treat high blood pressure and heart failure. Since it is not classified as a controlled substance, there are no DEA reporting requirements for its theft or significant loss.

D) Carisoprodol

Carisoprodol is classified as a Schedule IV controlled substance, which means that its theft or significant loss must be reported to the DEA. This requirement is in place to prevent misuse and diversion of controlled substances.

Conclusion

Carisoprodol is the only medication among the options that is classified as a controlled substance requiring DEA reporting for theft or significant loss. The other medications listed are not controlled substances, which is why they do not necessitate such reporting. Understanding the classification of medications is essential for compliance with federal regulations regarding controlled substances.